^
Association details:
| Biomarker: | BRAF T1799A |
|---|---|
| Cancer: | Melanoma |
| Drug: | sorafenib (Multi-tyrosine kinase inhibitor, pan-RAF inhibitor) + Ceraxa (nanoliposomal ceramide) (Apoptosis inducer, PP2A activator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combining Nanoliposomal Ceramide with Sorafenib Synergistically Inhibits Melanoma and Breast Cancer Cell Survival to Decrease Tumor Development
Excerpt:
Melanoma cells (UACC 903 and 1205 Lu) treated with 1.5 μmol/L sorafenib showed a 27% to 38% reduction in cell viability, whereas cells treated with 12.5 μmol/L nanoliposomal ceramide exhibited a 23% to 41% reduction in viability. In comparison, combined agents decreased cell viability by 65% to 84%, which was an approximately 2- to 4-fold increase compared with single agents (Fig. 3A).
DOI:
10.1158/1078-0432.CCR-07-4881
